Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from TuHURA Biosciences ( (HURA) ).
TuHURA Biosciences, Inc. is making significant strides in cancer immunotherapy with its IFx-2.0 technology, set to undergo a Phase 3 trial in advanced Merkel Cell Carcinoma. The company has entered a non-binding letter of intent to acquire Kineta’s innovative VISTA inhibiting antibody, KVA12123, to enhance its treatment pipeline. TuHURA’s strategic advancements include novel bi-specific antibodies and mRNA technologies, aiming to overcome resistance to current cancer immunotherapies. Key leadership hires aim to bolster clinical and operational execution as the company targets ambitious milestones for 2024-2025.
Learn more about HURA stock on TipRanks’ Stock Analysis page.
